Bach1, a protein that blocks the expression of genes associated with neuroprotection, has been implicated in Parkison's disease. Researchers say blocking Bach1 slows the deterioration of brain cells in preclinical models of Parkinson's disease.
Reductive stress promotes protein aggregation in neuroblastoma cells and impairs neurogenesis.
Fish model study found a potential target for the treatment of seasonal affective disorder (SAD). Researchers implicated NRF2 in seasonal depression and reported celastrol may help in the treatment of SAD.
Researchers report UroA, a microbial metabolite derived from a compound found in pomegranates and berries, can reduce and protect against inflammatory bowel disease.
A new study sheds light on how the circadian clock controls inflammatory response. By understanding the link between inflammation and circadian rhythm, researchers believe it may be most effective to target specific conditions at certain times of the day. The findings may also explain why those who experience body clock disruptions are more susceptible to inflammatory conditions.
Activating Nrf2 helps with the removal of LRRK2 and alpha synuclein, researchers report.
A drug usually used for the treatment of multiple sclerosis appears to increase the activity of Nrf2, a protein that protects the body from oxidative stress and inflammation associated with Parkinson's disease.
Researchers have successfully documented the initial steps in the transformation from stem cells to other cell types.
Researchers report urate stimulates astrocytes to activate a major antioxidant pathway believed to have a role in some neurodegenerative diseases.
A new study reports that a receptor targeted for treating neurodegenerative diseases also appears to play an important role in supporting the retina.
A new study indicates that quickly clearing away defective proteins in the brain could help prevent some neurodegenerative disorders.
